Ankylosing Spondylitis

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

Investigators evaluated sex differences in the effectiveness of tumor necrosis factor inhibitors in patients with ankylosing spondylitis.

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

Spinal fracture-free survival among patients with AS was not significantly affected by the use of bDMARD therapy.

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

Investigators examined the long-term safety and efficacy of a subcutaneous maintenance dose of secukinumab 150 and 300 mg.

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

Male gender and the Charlson Comorbidity Index score contributed significantly to fracture risk in this population.

Sign Up for Free e-newsletters